A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, and the drugmakers are moving closer to seeking regulatory approval to sell it.
Lilly said Tuesday that early results from a study that enrolled about 600 patients showed that its oral medication, baricitinib, proved superior to the established treatment methotrexate. The drugmakers are conducting several late-stage studies of baricitinib, which aims to treat patients with moderately to severely active rheumatoid arthritis.
The companies expect early results from a fourth late-stage study later this year, and a Lilly spokeswoman said they plan to submit the drug to the Food and Drug Administration before the end of 2015.
Rheumatoid arthritis is a chronic inflammatory disease that affects the joints and destroys soft tissue, cartilage and bone. It represents a major area of research for drug companies because it is chronic, meaning patients will likely take the drugs regularly for a long time.
Earlier this year, BMO Capital analyst Alex Arfaei predicted baricitinib could achieve $1.3 billion in annual sales by 2023.
Indianapolis-based Lilly bought the potential drug from Incyte in 2009 and is leading its development and the push to get it approved. Lilly will give Wilmington, Delaware-based Incyte milestone payments and royalties tied to annual sales if the drug is approved.
Lilly shares rose $1.45, or 1.8 percent, Tuesday morning, to $81.22 each. Incyte shares rose 5.4 percent, to $100.31.